Tradestie Institutional Equity Comparison Engine

VTGN vs LCTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin, Momentum & Technical while VTGN counters with relative strength in Options & Structure. Fundamentally, VTGN trades at N/M Forward P/E with -2543.1% operating margin (-46.5% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, VTGN sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
VTGN N/M vs LCTX 30.7x Fwd P/E
Growth & Margin Winner LCTX
Op Margin -2543.1% vs -280.3% ยท YoY -46.5% vs -61.0%
Momentum & Technical Winner LCTX
1Y -96.0% vs -53.7% ยท 52W Pos 0% vs 4%
Options & Structure Winner VTGN
UNCLASSIFIED (71st %ile IV) vs BREAKDOWN (100th %ile IV)
VTGN NASDAQ
Vistagen Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.19
-6.47% 1D
Market Cap $9.0M
1M Return -3.62%
1Y Return -95.97%
Forward P/E N/M
Unified AI Score
42.3 / 100 HOLD
Tech 20.0 Fund 52.0 Flow 69.0 Mom 54.0
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VTGN -95.97% LCTX -53.67% Spread: +42.3 pp (LCTX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period VTGN Revenue LCTX Revenue VTGN Op. Margin LCTX Op. Margin Margin Edge
FY2019 N/A $0M N/A -1106.0% LCTX
FY2020 N/A $0M N/A -1448.4% LCTX
FY2021 $0M $0M -1646.1% -1133.6% LCTX
FY2022 $0M $10M -4308.3% -153.2% LCTX
FY2023 N/A $10M N/A -276.5% LCTX
FY2024 $0M $10M -3103.5% -226.1% LCTX
FY2025 $0M $10M -11517.1% -251.6% LCTX
FY2026 $0M N/A -5683.7% N/A VTGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VTGN (1) vs LCTX (9)
Institutional Metric VTGN LCTX Criterion Row Winner
Market Capitalization Scale $9.0M $212.1M Larger Scale LCTX
Trailing P/E Ratio Valuation N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio Valuation N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY) Growth -46.5% -61.0% Higher Growth VTGN
Operating Margin (TTM) Profitability -2543.1% -280.3% Higher Margin LCTX
Net Profit Margin Profitability 0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency -144.9% 4.3% Higher ROE LCTX
52-Week Range Position Momentum 0% ($0โ€“$5) 4% ($1โ€“$2) Stronger Trend LCTX
Beta / 30D Volatility Risk Regime 1.23ฮฒ ยท 80% Vol 1.36ฮฒ ยท 79% Vol Lower Realized Risk LCTX
Unified Institutional Score Composite Signal 42.3 / 100 (HOLD) 58.9 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VTGN vs LCTX Buy Guide
VTGN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 71st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live VTGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VTGN nor LCTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.